<p>根据 Invesco Ltd.最近向 SEC 提交的 13F 文件，该公司在 2023 年第四季度减少了对诺和诺德公司（NYSE:NVO - 免费报告）32.9% 的持股。该公司在季度内出售了 171,244 股后，持有 349,208 股诺和诺德公司的股票。在最近的报告期结束时，Invesco Ltd.在诺和诺德公司的持股价值为 30,039,000 美元。</p>
<p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
<ul>
<li>Viking Therapeutics 股票上涨但难以维持涨幅</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也增加或减少了对 NVO 的持股。GQG Partners LLC 在第四季度将其在诺和诺德公司的持股增加了 74.7%。GQG Partners LLC 现在拥有 12,994,533 股诺和诺德公司的股票，价值 1,117,790,000 美元，此前在上个季度又收购了 5,556,460 股。Raymond James Financial Inc.在第四季度购买了诺和诺德公司的新股份，价值约 404,910,000 美元。Loomis Sayles &amp; Co. L P 在第四季度将其在诺和诺德公司的持股增加了 34.2%。Loomis Sayles &amp; Co. L P 现在拥有 11,571,686 股诺和诺德公司的股票，价值 995,397,000 美元，此前在上个季度又购买了 2,947,771 股。Clearbridge Investments LLC 在第四季度将其在诺和诺德公司的持股增加了 59.8%。Clearbridge Investments LLC 现在拥有 4,283,317 股诺和诺德公司的股票，价值 368,451,000 美元，此前在上个季度又购买了 1,602,549 股。最后，Sustainable Growth Advisers LP 在第四季度将其在诺和诺德公司的持股增加了 23.6%。Sustainable Growth Advisers LP 现在拥有 5,340,803 股诺和诺德公司的股票，价值 459,416,000 美元，此前在上个季度又购买了 1,021,498 股。对冲基金和其他机构投资者持有该公司 11.54% 的股票。</p>
<h2>诺和诺德公司价格表现</h2>
<p>周五，NYSE NVO 的开盘价为 57.99 美元。该股票的 50 日简单移动平均线为 76.03 美元，200 日简单移动平均线为 92.13 美元。诺和诺德公司的 12 个月低点为 57.28 美元，12 个月高点为 148.15 美元。该股票的市值为 2602.3 亿美元，市盈率为 17.63，市盈增长比率为 0.90，贝塔值为 0.61。该公司的债务与股本比率为 0.62，速动比率为 0.55，流动比率为 0.74。</p>
<ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
<p>诺和诺德公司（NYSE:NVO - 获取免费报告）最近在 2 月 5 日发布了季度财报。该公司报告季度每股收益为 0.91 美元，超出分析师一致预期的 0.88 美元，超出幅度为 0.03 美元。诺和诺德公司的股本回报率为 84.68%，净利润率为 34.81%。研究分析师预计诺和诺德公司今年的每股收益将达到 3.84 美元。</p>
<h2>诺和诺德公司增加股息</h2>
<p>该公司最近还披露了一项半年度股息，该股息于 4 月 8 日（星期二）支付。3 月 31 日（星期一）登记在册的股东获得每股 0.7874 美元的股息。这比诺和诺德公司之前的半年度股息 0.51 美元有所增加。除息日期为 3 月 31 日（星期一）。这代表了 1.2% 的股息收益率。诺和诺德公司的派息比率目前为 49.54%。</p>
<h2>分析师评级变动</h2>
<ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
<p>NVO 已成为多份分析师报告的主题。Kepler Capital Markets 在 3 月 13 日（星期四）的研究报告中将诺和诺德公司的股票评级从 “持有” 上调至 “买入”。StockNews.com 在周二的研究报告中将诺和诺德公司的股票评级从 “强力买入” 下调至 “买入”。Stifel Nicolaus 在 3 月 3 日（星期一）的研究报告中将诺和诺德公司的股票评级从 “买入” 下调至 “持有”。BMO Capital Markets 在周四的研究报告中重申了 “市场表现” 评级，并对诺和诺德公司的股票设定了 64.00 美元的目标价（之前为 105.00 美元）。最后，瑞银集团在 1 月 8 日（星期三）的报告中将诺和诺德公司的评级从 “卖出” 上调至 “买入”。一位投资分析师对该股票给予了 “卖出” 评级，四位给予了 “持有” 评级，六位给予了 “买入” 评级。根据 MarketBeat.com，诺和诺德公司目前的平均评级为 “持有”，平均目标价为 135.00 美元。</p>
<p><strong>查看我们对 NVO 的最新分析</strong></p>
<h2>诺和诺德公司公司简介</h2>
<p>（免费报告）</p>
<p>诺和诺德公司及其子公司从事药品的研究与开发、生产和分销业务，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，分别是糖尿病与肥胖护理和罕见疾病。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票超过诺和诺德公司</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>关税豁免为台湾半导体的反弹铺平道路</li>
<li>如何投资最佳的加拿大股票</li>
<li>缓解关税：三只股票从美元走弱中获益</li>
<li>稀释每股收益（Diluted EPS）是什么？</li>
<li>博通与苹果的关系：人工智能机会与关税风险的交汇</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
<p>在考虑诺和诺德公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺和诺德公司并不在名单上。</p>
<p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

景顺投资管理

诺和诺德公司

<p>景顺投资管理（Invesco Ltd.）在第四季度将其在诺和诺德公司（Novo Nordisk A/S，NYSE:NVO）的持股比例减少了 32.9%，在出售 171,244 股后，持有 349,208 股。其他机构投资者也调整了他们的持股，GQG Partners LLC 将其持股比例增加了 74.7%。诺和诺德的股票开盘价为 57.99 美元，市值为 2602.3 亿美元，市盈率为 17.63。该公司最近报告的每股收益（EPS）为 0.91 美元，超出预期，并将其半年度股息提高至每股 0.7874 美元</p>

<p>Invesco Ltd. lessened its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 32.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 349,208 shares of the company's stock after selling 171,244 shares during the quarter. Invesco Ltd.'s holdings in Novo Nordisk A/S were worth $30,039,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据 Invesco Ltd.最近向 SEC 提交的 13F 文件，该公司在 2023 年第四季度减少了对诺和诺德公司（NYSE:NVO - 免费报告）32.9% 的持股。该公司在季度内出售了 171,244 股后，持有 349,208 股诺和诺德公司的股票。在最近的报告期结束时，Invesco Ltd.在诺和诺德公司的持股价值为 30,039,000 美元。</p>
</div><p>Get <strong>Novo Nordisk A/S</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>诺和诺德公司</strong> 的提醒：</p>
</div><ul>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>Viking Therapeutics 股票上涨但难以维持涨幅</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. GQG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 74.7% during the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after acquiring an additional 5,556,460 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $404,910,000. Loomis Sayles &amp; Co. L P lifted its holdings in shares of Novo Nordisk A/S by 34.2% during the 4th quarter. Loomis Sayles &amp; Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after buying an additional 2,947,771 shares during the last quarter. Clearbridge Investments LLC grew its stake in shares of Novo Nordisk A/S by 59.8% in the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after buying an additional 1,602,549 shares in the last quarter. Finally, Sustainable Growth Advisers LP increased its holdings in Novo Nordisk A/S by 23.6% in the fourth quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company's stock worth $459,416,000 after buying an additional 1,021,498 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也增加或减少了对 NVO 的持股。GQG Partners LLC 在第四季度将其在诺和诺德公司的持股增加了 74.7%。GQG Partners LLC 现在拥有 12,994,533 股诺和诺德公司的股票，价值 1,117,790,000 美元，此前在上个季度又收购了 5,556,460 股。Raymond James Financial Inc.在第四季度购买了诺和诺德公司的新股份，价值约 404,910,000 美元。Loomis Sayles &amp; Co. L P 在第四季度将其在诺和诺德公司的持股增加了 34.2%。Loomis Sayles &amp; Co. L P 现在拥有 11,571,686 股诺和诺德公司的股票，价值 995,397,000 美元，此前在上个季度又购买了 2,947,771 股。Clearbridge Investments LLC 在第四季度将其在诺和诺德公司的持股增加了 59.8%。Clearbridge Investments LLC 现在拥有 4,283,317 股诺和诺德公司的股票，价值 368,451,000 美元，此前在上个季度又购买了 1,602,549 股。最后，Sustainable Growth Advisers LP 在第四季度将其在诺和诺德公司的持股增加了 23.6%。Sustainable Growth Advisers LP 现在拥有 5,340,803 股诺和诺德公司的股票，价值 459,416,000 美元，此前在上个季度又购买了 1,021,498 股。对冲基金和其他机构投资者持有该公司 11.54% 的股票。</p>
</div><h2>Novo Nordisk A/S Price Performance</h2>
<div class="lb-trans"><h2>诺和诺德公司价格表现</h2>
</div><p>NYSE NVO opened at $57.99 on Friday. The stock has a 50-day simple moving average of $76.03 and a 200 day simple moving average of $92.13. Novo Nordisk A/S has a twelve month low of $57.28 and a twelve month high of $148.15. The stock has a market capitalization of $260.23 billion, a PE ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.</p>
<div class="lb-trans"><p>周五，NYSE NVO 的开盘价为 57.99 美元。该股票的 50 日简单移动平均线为 76.03 美元，200 日简单移动平均线为 92.13 美元。诺和诺德公司的 12 个月低点为 57.28 美元，12 个月高点为 148.15 美元。该股票的市值为 2602.3 亿美元，市盈率为 17.63，市盈增长比率为 0.90，贝塔值为 0.61。该公司的债务与股本比率为 0.62，速动比率为 0.55，流动比率为 0.74。</p>
</div><ul>
<li>Which Healthcare Stock Is the Best Buy Right Now?</li>
</ul>
<div class="lb-trans"><ul>
<li>目前哪个医疗保健股票是最佳买入？</li>
</ul>
</div><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.</p>
<div class="lb-trans"><p>诺和诺德公司（NYSE:NVO - 获取免费报告）最近在 2 月 5 日发布了季度财报。该公司报告季度每股收益为 0.91 美元，超出分析师一致预期的 0.88 美元，超出幅度为 0.03 美元。诺和诺德公司的股本回报率为 84.68%，净利润率为 34.81%。研究分析师预计诺和诺德公司今年的每股收益将达到 3.84 美元。</p>
</div><h2>Novo Nordisk A/S Increases Dividend</h2>
<div class="lb-trans"><h2>诺和诺德公司增加股息</h2>
</div><p>The business also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's payout ratio is presently 49.54%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项半年度股息，该股息于 4 月 8 日（星期二）支付。3 月 31 日（星期一）登记在册的股东获得每股 0.7874 美元的股息。这比诺和诺德公司之前的半年度股息 0.51 美元有所增加。除息日期为 3 月 31 日（星期一）。这代表了 1.2% 的股息收益率。诺和诺德公司的派息比率目前为 49.54%。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通过进入减肥市场提升投资组合</li>
</ul>
</div><p>NVO has been the subject of a number of analyst reports. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Thursday, March 13th. StockNews.com lowered shares of Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, March 3rd. BMO Capital Markets reaffirmed a &#34;market perform&#34; rating and issued a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday. Finally, UBS Group raised Novo Nordisk A/S from a &#34;sell&#34; rating to a &#34;buy&#34; rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, Novo Nordisk A/S currently has an average rating of &#34;Hold&#34; and an average price target of $135.00.</p>
<div class="lb-trans"><p>NVO 已成为多份分析师报告的主题。Kepler Capital Markets 在 3 月 13 日（星期四）的研究报告中将诺和诺德公司的股票评级从 “持有” 上调至 “买入”。StockNews.com 在周二的研究报告中将诺和诺德公司的股票评级从 “强力买入” 下调至 “买入”。Stifel Nicolaus 在 3 月 3 日（星期一）的研究报告中将诺和诺德公司的股票评级从 “买入” 下调至 “持有”。BMO Capital Markets 在周四的研究报告中重申了 “市场表现” 评级，并对诺和诺德公司的股票设定了 64.00 美元的目标价（之前为 105.00 美元）。最后，瑞银集团在 1 月 8 日（星期三）的报告中将诺和诺德公司的评级从 “卖出” 上调至 “买入”。一位投资分析师对该股票给予了 “卖出” 评级，四位给予了 “持有” 评级，六位给予了 “买入” 评级。根据 MarketBeat.com，诺和诺德公司目前的平均评级为 “持有”，平均目标价为 135.00 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on NVO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 NVO 的最新分析</strong></p>
</div><h2>Novo Nordisk A/S Company Profile</h2>
<div class="lb-trans"><h2>诺和诺德公司公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p>
<div class="lb-trans"><p>诺和诺德公司及其子公司从事药品的研究与开发、生产和分销业务，覆盖欧洲、中东、非洲、中国大陆、香港、台湾、北美及国际市场。它分为两个部门，分别是糖尿病与肥胖护理和罕见疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Novo Nordisk A/S</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>How to Invest in the Best Canadian Stocks</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>What is diluted earnings per share (Diluted EPS)?</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过诺和诺德公司</li>
<li>如何知道一只股票是否支付股息以及何时支付</li>
<li>关税豁免为台湾半导体的反弹铺平道路</li>
<li>如何投资最佳的加拿大股票</li>
<li>缓解关税：三只股票从美元走弱中获益</li>
<li>稀释每股收益（Diluted EPS）是什么？</li>
<li>博通与苹果的关系：人工智能机会与关税风险的交汇</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺和诺德公司吗？</h2>
</div><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺和诺德公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而诺和诺德公司并不在名单上。</p>
</div><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺和诺德公司目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

景顺投资管理有限公司减少了其在诺和诺德公司（NYSE:NVO）的股票持仓